North America Pharmaceuticals Market Size and Forecast (2021 - 2031)
The North American Pharmaceuticals Market is poised for significant growth, with projections indicating it will reach approximately USD 1,663.4 billion by 2031, up from USD 990.7 billion in 2024. This growth trajectory reflects a compound annual growth rate (CAGR) of 7.7% from 2025 to 2031, driven by various factors that are reshaping the landscape of the pharmaceutical industry in the region.
Market Overview
The North American pharmaceuticals market is primarily divided into three key countries: the United States, Canada, and Mexico. The growth of this market can be attributed to several critical factors, including the rising incidence of cancer, increased investments in research and development, and a surge in new product launches. Furthermore, strategic initiatives such as the introduction of innovative products, obtaining regulatory approvals, and forming collaborations and acquisitions are significantly contributing to the market's expansion.
A major driver of this market is the aging population in North America. As the demographic shifts towards an older population, the prevalence of chronic diseases and conditions that necessitate ongoing pharmaceutical treatment is expected to rise. According to the U.S. Census Bureau, by 2030, one in five Americans will be aged 65 or older, which will inevitably increase the demand for medications targeting age-related health issues.
Innovations and Regulatory Environment
The rapid advancements in biotechnology are also propelling the pharmaceuticals market forward. The emergence of biologic drugs, personalized medicine, and gene therapies has transformed the treatment landscape for various diseases, including cancer, rare genetic disorders, and autoimmune diseases. Notable innovations such as CAR-T cell therapies and monoclonal antibodies are gaining popularity and acceptance in the market.
The presence of robust regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, plays a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products. The stringent regulatory processes have led to a consistent influx of new drugs into the market, fostering innovation and consumer trust.
Moreover, the digital transformation of healthcare, characterized by the rise of telemedicine and digital therapeutics, is creating new opportunities for pharmaceutical companies. Collaborations with digital health providers can lead to integrated solutions for managing chronic diseases, personalized treatment plans, and remote patient monitoring, further enhancing the market's growth potential.
Market Segmentation
The North American pharmaceuticals market can be segmented based on various criteria:
Looking ahead, the North American pharmaceuticals market is expected to undergo significant transformations. Emerging regional powers are likely to redefine pharmaceutical dominance, shifting innovation and market focus beyond traditional centers. Supply chains are anticipated to diversify strategically to mitigate risks and enhance agility in response to global uncertainties. Regulatory frameworks will evolve rapidly, incorporating digital tools and fostering cross-border collaborations to streamline drug approvals.
According to Oxford Economics, the global pharmaceuticals market, valued at USD 1.5 trillion in 2023, is on a steady growth trajectory, with expected expansions of 3% in 2024, 4% in 2025, and 3.6% in 2026. In the U.S., pharmaceutical growth is projected to moderate to 2.9% in 2024 and 2.5% in 2025, influenced by increased reshoring efforts for active pharmaceutical ingredient (API) production due to supply chain vulnerabilities.
The rising demand for weight-loss drugs, anticipated to reach USD 80 billion by 2030, is also reshaping market priorities. The pharmaceutical industry is experiencing a fundamental transformation driven by shifting global power dynamics, supply chain diversification, and evolving regulations. The increasing demand for specialized medicines, coupled with intensified mergers and acquisitions, is reshaping the competitive landscape. Challenges such as regulatory complexities and cost pressures remain, necessitating greater agility and innovation within the industry.
In summary, the North American pharmaceuticals market is on a robust growth path, characterized by demographic shifts, technological advancements, and evolving healthcare needs. The future will be defined by the industry's ability to adapt to geopolitical, technological, and healthcare changes on a global scale.
Market Overview
The North American pharmaceuticals market is primarily divided into three key countries: the United States, Canada, and Mexico. The growth of this market can be attributed to several critical factors, including the rising incidence of cancer, increased investments in research and development, and a surge in new product launches. Furthermore, strategic initiatives such as the introduction of innovative products, obtaining regulatory approvals, and forming collaborations and acquisitions are significantly contributing to the market's expansion.
A major driver of this market is the aging population in North America. As the demographic shifts towards an older population, the prevalence of chronic diseases and conditions that necessitate ongoing pharmaceutical treatment is expected to rise. According to the U.S. Census Bureau, by 2030, one in five Americans will be aged 65 or older, which will inevitably increase the demand for medications targeting age-related health issues.
Innovations and Regulatory Environment
The rapid advancements in biotechnology are also propelling the pharmaceuticals market forward. The emergence of biologic drugs, personalized medicine, and gene therapies has transformed the treatment landscape for various diseases, including cancer, rare genetic disorders, and autoimmune diseases. Notable innovations such as CAR-T cell therapies and monoclonal antibodies are gaining popularity and acceptance in the market.
The presence of robust regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, plays a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products. The stringent regulatory processes have led to a consistent influx of new drugs into the market, fostering innovation and consumer trust.
Moreover, the digital transformation of healthcare, characterized by the rise of telemedicine and digital therapeutics, is creating new opportunities for pharmaceutical companies. Collaborations with digital health providers can lead to integrated solutions for managing chronic diseases, personalized treatment plans, and remote patient monitoring, further enhancing the market's growth potential.
Market Segmentation
The North American pharmaceuticals market can be segmented based on various criteria:
- By Molecule Type: The market is divided into Small Molecule and Biological/Biosimilar Products, with Small Molecule products holding the largest market share in 2024.
- By Indication: The market is categorized into Metabolic Diseases, Cancer, Immunology, Respiratory Disorders, Cardiovascular Disorders, Neurology Disorders, Rare Diseases, and Others, with Cancer being the leading segment in 2024.
- By Product: The market is split into Branded and Generic products, where Branded products dominate the market share.
- By Type: The market is classified into Prescription and Over-the-Counter (OTC) Drugs, with Prescription drugs leading in market share.
- By Distribution Channel: The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Hospital Pharmacies holding the largest share.
Looking ahead, the North American pharmaceuticals market is expected to undergo significant transformations. Emerging regional powers are likely to redefine pharmaceutical dominance, shifting innovation and market focus beyond traditional centers. Supply chains are anticipated to diversify strategically to mitigate risks and enhance agility in response to global uncertainties. Regulatory frameworks will evolve rapidly, incorporating digital tools and fostering cross-border collaborations to streamline drug approvals.
According to Oxford Economics, the global pharmaceuticals market, valued at USD 1.5 trillion in 2023, is on a steady growth trajectory, with expected expansions of 3% in 2024, 4% in 2025, and 3.6% in 2026. In the U.S., pharmaceutical growth is projected to moderate to 2.9% in 2024 and 2.5% in 2025, influenced by increased reshoring efforts for active pharmaceutical ingredient (API) production due to supply chain vulnerabilities.
The rising demand for weight-loss drugs, anticipated to reach USD 80 billion by 2030, is also reshaping market priorities. The pharmaceutical industry is experiencing a fundamental transformation driven by shifting global power dynamics, supply chain diversification, and evolving regulations. The increasing demand for specialized medicines, coupled with intensified mergers and acquisitions, is reshaping the competitive landscape. Challenges such as regulatory complexities and cost pressures remain, necessitating greater agility and innovation within the industry.
In summary, the North American pharmaceuticals market is on a robust growth path, characterized by demographic shifts, technological advancements, and evolving healthcare needs. The future will be defined by the industry's ability to adapt to geopolitical, technological, and healthcare changes on a global scale.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. PHARMACEUTICAL MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 North America
4.2.1.1 United States
4.2.1.2 Canada
4.2.1.3 Mexico
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. NORTH AMERICA PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS
5.1 North America Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. PHARMACEUTICAL MARKET – NORTH AMERICA ANALYSIS
6.1 North America Pharmaceutical Market Revenue (US$ Billion), 2021–2031
6.2 North America Pharmaceutical Market Forecast Analysis
7. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT
9.1 Branded
9.1.1 Overview
9.1.2 Branded: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 Generic
9.2.1 Overview
9.2.2 Generic: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY TYPE
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12. NORTH AMERICA PHARMACEUTICAL MARKET – COUNTRY ANALYSIS
12.1 North America
12.1.1 North America Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 North America Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 United States: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.2.1 United States: North America Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 United States: North America Pharmaceutical Market Share – by Indication
12.1.1.2.3 United States: North America Pharmaceutical Market Share – by Product
12.1.1.2.4 United States: North America Pharmaceutical Market Share – by Type
12.1.1.2.5 United States: North America Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.3.1 Canada: North America Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Canada: North America Pharmaceutical Market Share – by Indication
12.1.1.3.3 Canada: North America Pharmaceutical Market Share – by Product
12.1.1.3.4 Canada: North America Pharmaceutical Market Share – by Type
12.1.1.3.5 Canada: North America Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.4.1 Mexico: North America Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 Mexico: North America Pharmaceutical Market Share – by Indication
12.1.1.4.3 Mexico: North America Pharmaceutical Market Share – by Product
12.1.1.4.4 Mexico: North America Pharmaceutical Market Share – by Type
12.1.1.4.5 Mexico: North America Pharmaceutical Market Share – by Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1 Company Market Share Analysis
14. INDUSTRY LANDSCAPE
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. COMPANY PROFILES
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. APPENDIX
16.1 Glossary of Terms
16.2 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
3.3 Assumptions and Limitations
4. PHARMACEUTICAL MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Regulatory Landscape
4.2.1 North America
4.2.1.1 United States
4.2.1.2 Canada
4.2.1.3 Mexico
4.3 List of Key Suppliers:
4.4 Average selling Price:
4.5 Sourcing Strategy:
4.6 Market Entry Barriers in the Global Pharmaceutical Market:
4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:
5. NORTH AMERICA PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS
5.1 North America Pharmaceutical Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:
6. PHARMACEUTICAL MARKET – NORTH AMERICA ANALYSIS
6.1 North America Pharmaceutical Market Revenue (US$ Billion), 2021–2031
6.2 North America Pharmaceutical Market Forecast Analysis
7. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE
7.1 Small Molecule
7.1.1 Overview
7.1.2 Small Molecule: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
7.2 Biological and Biosimilar Products
7.2.1 Overview
7.2.2 Biological and Biosimilar Products: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION
8.1 Metabolic Diseases
8.1.1 Overview
8.1.2 Metabolic Diseases: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.2 Cancer
8.2.1 Overview
8.2.2 Cancer: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.3 Immunology
8.3.1 Overview
8.3.2 Immunology: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.4 Respiratory Disorder
8.4.1 Overview
8.4.2 Respiratory Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.5 Cardiovascular Disorder
8.5.1 Overview
8.5.2 Cardiovascular Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.6 Neurology Disorder
8.6.1 Overview
8.6.2 Neurology Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.7 Rare Disease
8.7.1 Overview
8.7.2 Rare Disease: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
8.8 Others
8.8.1 Overview
8.8.2 Others: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT
9.1 Branded
9.1.1 Overview
9.1.2 Branded: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
9.2 Generic
9.2.1 Overview
9.2.2 Generic: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY TYPE
10.1 Prescription
10.1.1 Overview
10.1.2 Prescription: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
10.2 OTC Drugs
10.2.1 Overview
10.2.2 OTC Drugs: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11. NORTH AMERICA PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12. NORTH AMERICA PHARMACEUTICAL MARKET – COUNTRY ANALYSIS
12.1 North America
12.1.1 North America Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.1 North America Pharmaceutical Market – Revenue and Forecast Analysis – by Country
12.1.1.2 United States: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.2.1 United States: North America Pharmaceutical Market Share – by Molecule Type
12.1.1.2.2 United States: North America Pharmaceutical Market Share – by Indication
12.1.1.2.3 United States: North America Pharmaceutical Market Share – by Product
12.1.1.2.4 United States: North America Pharmaceutical Market Share – by Type
12.1.1.2.5 United States: North America Pharmaceutical Market Share – by Distribution Channel
12.1.1.3 Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.3.1 Canada: North America Pharmaceutical Market Share – by Molecule Type
12.1.1.3.2 Canada: North America Pharmaceutical Market Share – by Indication
12.1.1.3.3 Canada: North America Pharmaceutical Market Share – by Product
12.1.1.3.4 Canada: North America Pharmaceutical Market Share – by Type
12.1.1.3.5 Canada: North America Pharmaceutical Market Share – by Distribution Channel
12.1.1.4 Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
12.1.1.4.1 Mexico: North America Pharmaceutical Market Share – by Molecule Type
12.1.1.4.2 Mexico: North America Pharmaceutical Market Share – by Indication
12.1.1.4.3 Mexico: North America Pharmaceutical Market Share – by Product
12.1.1.4.4 Mexico: North America Pharmaceutical Market Share – by Type
12.1.1.4.5 Mexico: North America Pharmaceutical Market Share – by Distribution Channel
13. COMPETITIVE LANDSCAPE
13.1 Company Market Share Analysis
14. INDUSTRY LANDSCAPE
14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies
15. COMPANY PROFILES
15.1 Johnson & Johnson
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Merck & Co Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Eli Lilly and Co
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Financial Overview
15.4.4 SWOT Analysis
15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 ESTEVE
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 UCB SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Viatris Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 AstraZeneca Plc
15.11.1 1Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Sanofi SA
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 GSK Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Novartis AG
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
15.15.6 Key Developments
15.16 AbbVie Inc
15.16.1 Key Facts
15.16.2 Business Description
15.16.3 Products and Services
15.16.4 Financial Overview
15.16.5 SWOT Analysis
15.16.6 Key Developments
16. APPENDIX
16.1 Glossary of Terms
16.2 About The Insight Partners
LIST OF TABLES
Table 1. North America Pharmaceutical Market Segmentation
Table 2. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 6. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Product
Table 7. Key brands facing patent expirations
Table 8. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 9. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 10. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 11. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 12. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 13. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 14. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 19. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 20. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 21. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 22. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 23. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 24. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 25. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 26. Company Market Share Analysis
Table 27. Glossary of Terms, Pharmaceutical Market
Table 1. North America Pharmaceutical Market Segmentation
Table 2. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Table 3. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Molecule Type
Table 4. Table: Top-Selling Drugs in 2021
Table 5. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Indication
Table 6. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Product
Table 7. Key brands facing patent expirations
Table 8. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Type
Table 9. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Distribution Channel
Table 10. North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion) – by Country
Table 11. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 12. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 13. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 14. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 15. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 16. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 17. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 18. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 19. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 20. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 21. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Molecule Type
Table 22. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Indication
Table 23. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Product
Table 24. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Type
Table 25. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US$ Billion) – by Distribution Channel
Table 26. Company Market Share Analysis
Table 27. Glossary of Terms, Pharmaceutical Market
LIST OF FIGURES
Figure 1. North America Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Pharmaceutical Market Revenue (US$ Billion), 2021–2031
Figure 5. North America Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Biological and Biosimilar Products: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. North America Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Cancer: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Immunology: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Respiratory Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Cardiovascular Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 14. Neurology Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Rare Disease: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Others: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. North America Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Generic: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. North America Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. OTC Drugs: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 23. North America Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Retail Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 26. Online Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. North America Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 29. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 30. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 1. North America Pharmaceutical Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Pharmaceutical Market Revenue (US$ Billion), 2021–2031
Figure 5. North America Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)
Figure 6. Small Molecule: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 7. Biological and Biosimilar Products: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 8. North America Pharmaceutical Market Share (%) – by Indication (2024 and 2031)
Figure 9. Metabolic Diseases: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 10. Cancer: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 11. Immunology: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 12. Respiratory Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 13. Cardiovascular Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 14. Neurology Disorder: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 15. Rare Disease: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 16. Others: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 17. North America Pharmaceutical Market Share (%) – by Product (2024 and 2031)
Figure 18. Branded: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 19. Generic: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 20. North America Pharmaceutical Market Share (%) – by Type (2024 and 2031)
Figure 21. Prescription: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 22. OTC Drugs: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 23. North America Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)
Figure 24. Hospital Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 25. Retail Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 26. Online Pharmacies: North America Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US$ Billion)
Figure 27. North America Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 28. United States: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 29. Canada: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
Figure 30. Mexico: North America Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US$ Billion)
